Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
The April 2026 FDA action removes them from the Category 2 restricted compounding list effective April 23, 2026, and the FDAs Pharmacy Compounding Advisory Committee will review their compounding eligibility under 503A at its July 23-24, 2026 meeting
Contraindications and Precautions While GHK-Cu is generally well-tolerated, certain conditions warrant caution or avoidance
When used appropriately under physician guidance as part of comprehensive metabolic optimization strategies, AOD-9604 may provide a research-based tool for individuals committed to evidence-informed approaches to body composition improvement
Molecular Profile (CAS 137525-51-0) Storage, Handling, and Reconstitution of the BPC-157 Peptide Store lyophilized powder at -20 C, desiccated, protected from light
